Catalyst Pharmaceuticals Stock Market Value
| CPRX Stock | USD 24.19 0.08 0.33% |
| Symbol | Catalyst |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. Projected growth potential of Catalyst fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Catalyst Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.2 | Earnings Share 1.71 | Revenue Per Share | Quarterly Revenue Growth 0.153 | Return On Assets |
Understanding Catalyst Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Catalyst's accounting equity. The concept of intrinsic value - what Catalyst Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Catalyst Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Catalyst Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Catalyst Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Catalyst Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Catalyst Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Catalyst Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Catalyst Pharmaceuticals.
| 11/27/2025 |
| 02/25/2026 |
If you would invest 0.00 in Catalyst Pharmaceuticals on November 27, 2025 and sell it all today you would earn a total of 0.00 from holding Catalyst Pharmaceuticals or generate 0.0% return on investment in Catalyst Pharmaceuticals over 90 days. Catalyst Pharmaceuticals is related to or competes with Mineralys Therapeutics, Apellis Pharmaceuticals, Beam Therapeutics, Adaptive Biotechnologies, Scholar Rock, Ideaya Biosciences, and Recursion Pharmaceuticals. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing ... More
Catalyst Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Catalyst Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Catalyst Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.8 | |||
| Information Ratio | 0.0077 | |||
| Maximum Drawdown | 8.26 | |||
| Value At Risk | (3.20) | |||
| Potential Upside | 3.0 |
Catalyst Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalyst Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Catalyst Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Catalyst Pharmaceuticals historical prices to predict the future Catalyst Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0551 | |||
| Jensen Alpha | 0.0359 | |||
| Total Risk Alpha | (0.11) | |||
| Sortino Ratio | 0.0076 | |||
| Treynor Ratio | 0.1385 |
Catalyst Pharmaceuticals February 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0551 | |||
| Market Risk Adjusted Performance | 0.1485 | |||
| Mean Deviation | 1.39 | |||
| Semi Deviation | 1.68 | |||
| Downside Deviation | 1.8 | |||
| Coefficient Of Variation | 1553.37 | |||
| Standard Deviation | 1.78 | |||
| Variance | 3.18 | |||
| Information Ratio | 0.0077 | |||
| Jensen Alpha | 0.0359 | |||
| Total Risk Alpha | (0.11) | |||
| Sortino Ratio | 0.0076 | |||
| Treynor Ratio | 0.1385 | |||
| Maximum Drawdown | 8.26 | |||
| Value At Risk | (3.20) | |||
| Potential Upside | 3.0 | |||
| Downside Variance | 3.24 | |||
| Semi Variance | 2.83 | |||
| Expected Short fall | (1.46) | |||
| Skewness | (0.25) | |||
| Kurtosis | 0.0483 |
Catalyst Pharmaceuticals Backtested Returns
At this stage we consider Catalyst Stock to be very steady. Catalyst Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0391, which signifies that the company had a 0.0391 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Catalyst Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Catalyst Pharmaceuticals' Risk Adjusted Performance of 0.0551, downside deviation of 1.8, and Mean Deviation of 1.39 to double-check if the risk estimate we provide is consistent with the expected return of 0.0724%. Catalyst Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.76, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Catalyst Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Catalyst Pharmaceuticals is expected to be smaller as well. Catalyst Pharmaceuticals right now shows a risk of 1.85%. Please confirm Catalyst Pharmaceuticals potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Catalyst Pharmaceuticals will be following its price patterns.
Auto-correlation | 0.37 |
Below average predictability
Catalyst Pharmaceuticals has below average predictability. Overlapping area represents the amount of predictability between Catalyst Pharmaceuticals time series from 27th of November 2025 to 11th of January 2026 and 11th of January 2026 to 25th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Catalyst Pharmaceuticals price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Catalyst Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | 0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 0.44 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.